Sorafenib is the unique accepted molecular targeted drug for the treatment of patients in advanced stage of hepatocellular carcinoma. The current study evaluated cell signaling regulation of endoplasmic reticulum (ER) stress, c-Jun-N-terminal kinase (JNK), Akt, and 5′AMP-activated protein kinase (AMPK) leading to autophagy and apoptosis induced by sorafenib. Sorafenib induced early (3-12 hr) ER stress characterized by an increase of Ser51 P-eIF2α/eIF2α, C/EBP homologous protein (CHOP), IRE1α, and sXBP1, but a decrease of activating transcription factor 6 expression, overall temporally associated with the increase of Thr183,Tyr185 P-JNK1/2/ JNK1/2, Thr172 P-AMPKα, Ser413 P-Foxo3a, Thr308 P-AKt/AKt and 
Sorafenib is the unique accepted molecular targeted drug for the treatment of patients in advanced stage of hepatocellular carcinoma. The current study evaluated cell signaling regulation of endoplasmic reticulum (ER) stress, c-Jun-N-terminal kinase (JNK), Akt, and 5′AMP-activated protein kinase (AMPK) leading to autophagy and apoptosis induced by sorafenib. Sorafenib induced early (3-12 hr) ER stress characterized by an increase of Ser51 P-eIF2α/eIF2α, C/EBP homologous protein (CHOP), IRE1α, and sXBP1, but a decrease of activating transcription factor 6 expression, overall temporally associated with the increase of Thr183,Tyr185 P-JNK1/2/ JNK1/2, Thr172 P-AMPKα, Ser413 P-Foxo3a, Thr308 P-AKt/AKt and worldwide (Llovet et al., 2016; Torre et al., 2015) . HCC develops within a cirrhotic liver in 80%-90% of cases that influences therapeutic decisions (Fattovich, Stroffolini, Zagni, & Donato, 2004; Sanyal, Yoon, & Lencioni, 2010) . The difficulty in forming an early diagnosis, at the first stage of the disease, contributes to the poor response of patients to current clinical treatments. Currently, only one-third of newly diagnosed patients with HCC are an at early stage (0 or A), according to the Barcelona Clinic Liver Cancer (BCLC) staging system, and are eligible for potential curative therapies such as local ablation, resection, or orthotopic liver transplantation with a 5-year survival rate of 50%-80% (Bruix, Reig, & Sherman, 2016) . The recommended first-line treatment for patients with locally advanced/ metastatic disease (BLCL C) is sorafenib with a mean overall survival of 11 months (Cheng et al., 2009; Llovet et al., 2008) .
Sorafenib inhibits tyrosine kinase receptors such as vascular endothelial growth factor receptor (VEGFR) 2, VEGFR 3, plateletderived growth factor receptor-β (PDGFR-β), Flt3 and c-Kit, as well as molecular components of the Raf/MEK/extracellular signal-regulated kinase (ERK) signaling pathway (Cervello et al., 2012) . Different studies have suggested that the increased susceptibility to cell death by sorafenib is associated with down-regulation of cell survival pathways in hepatoma cells (Prieto-Dominguez et al., 2016) . In particular, Chen et al. (2010) showed that sorafenib enhanced TRAIL-induced cell death through SH2 domain-containing tyrosine phosphatase (SHP-1)-dependent reduction of signal transducers and activators of transcription type 3 (STAT3) phosphorylation ( Tyr705 STAT3) and related proteins members myeloid cell leukemia-1 (Mcl-1), survivin, and cyclin D1 in hepatoma cells. Sorafenib-induced cell death is also related to upregulation of the proapoptotic "BH3-domain only" PUMA and BIM, as well as a decrease of Mcl-1 and survivin (Fernando et al., 2012) . It has also been shown that c-Jun-N-terminal kinase (JNK)-dependent GADD45β (Ou et al., 2010) and PUMA (Fernando et al., 2012) expressions are also involved in the proapoptotic properties of sorafenib in HCC cells. Shimizu et al. (2012) showed that sorafenib enhanced autophagy, pharmacological inhibition due to which increased apoptosis and decreased cell viability in sorafenib-treated Huh7, HLF, and PLC/PRF/5 cells. However, other studies did not find a relationship between autophagy induction and resistance to treatment in sorafenibtreated HCC cells (Fischer, Wang, Vlada, Kim, & Behrns, 2014) . The current study showed that the induction of autophagy in sorafenibtreated HepG2 cells is related to IRE-1 and eIF2α-dependent ER stress, JNK and 5′AMP-activated protein kinase (AMPK)-dependent signaling.
The shift from autophagy to apoptosis is related to a decline of Beclin-1, Bcl-2, Mcl-1, Bcl-xL, Bcl-2, and tBid and the increase of proapoptotic BimEL, Bak, and Bax. 
| MATERIAL AND METHODS

| Chemical and reagents
| Primary human hepatocytes, cell lines, and culture conditions
Human hepatocytes were prepared from liver biopsies obtained from three patients (two females and one male, aged 66 ± 3.0 years) submitted to surgical resection for liver tumors after obtaining the patients' written consent. Hepatocytes isolation was based on a two-step collagenase procedure (Pichard et al., 2006 
| Immunohistochemistry
Tumor tissue sections (5 µm) were obtained to analyze the expression of α-smooth muscle actin (α-sma), Ki67, CD31, and CD34 by immunohistochemistry. Sections were deparaffinized, hydrated through graded ethanol steps, briefly rinsed in water, and blocked at room temperature using TBSA-BSAT (10 mM Tris, 0.9% NaCl, 0.02% sodium azide, 2%
bovine serum albumin and 0.1% Triton-X100). Slices were incubated overnight at room temperature with primary antibodies against 1:250 α- 
| Measurement of cell death
Caspase-3-associated activities were determined using CaspaseGlo® 3 Assay Systems (G8091; Promega, Madison). Cells were treated with Caspase-Glo® 3 in an "add-mix-measure" format resulting in cell lysis, caspase-3-dependent cleavage of the substrate and generation of a "glow-type" luminescent signal. The signal generated was proportional to the amount of caspase activity. The values are extrapolated into a calibration curve included in the assay.
Cell death in tissue sections was determined using the DeadEnd™ fluorometric terminal deoxynucleotidyl transferase mediated dUTP nick-end labeling (TUNEL) System (G3250, Promega) that measures the fragmented DNA of apoptotic cells by catalytically incorporating fluorescein-12-dUTP at 3′-OH DNA ends using the enzyme terminal deoxynucleotidyl transferase (TdT), which forms a polymeric tail using the principle of the TUNEL assay. The fluorescein-12-dUTPlabeled DNA was visualized using an Olympus BX61 microscope.
Fluorescence quantification was performed using Leica Application Suite Advanced Fluorescence software and the ImageJ software. 
| Cell proliferation
| Assessment of protein translation
The protocol adapted for polysome preparation of HepG2 cells was the one we routinely employ for yeast cells (Kressler, de la Cruz, Rojo, & Linder, 1997) . Briefly, HepG2 cells were grown to 80% confluency in 175 cm 2 dishes as described above. Normally, two dishes were used per condition assayed. Before harvesting the cells, 200 µg/ml cycloheximide was added and incubated for 5 min at 37°C. Each dish was then placed on ice, the medium was collected, and the cultures washed twice with PBS without Ca 2+ and Mg 2+ containing 200 µg/ml cycloheximide. Then, 600 µl of lysis buffer (10 mM Tris-HCl, pH7.4, 150 mM NaCl, 10 mM MgCl 2 , 200 µg/ml cycloheximide, 200 µg/ml heparin, 2 mM dithiothreitol (DTT), 0.5% NP40) was added to one dish, cells were scraped, and transferred to the second dish. After scraping the cells corresponding to the second dish, the whole juice was transferred to a 1.5 ml-Eppendorf tube. The tubes were incubated at 4°C with gentle end-over-end rotation for 10 min and then centrifuged at 16,000g for 8 min at 4°C in a refrigerated microfuge. The corresponding supernatants were recovered, and the A 260 was measured using a NanoDrop ND-1000 
| Statistical analysis
All results are expressed as the mean ± standard error of the mean of independent experiments (n = 4-10). Data were compared using the analysis of variance with the least significant difference's test as post- F I G U R E 2 Regulation of caspase-3 activity (a) and cell proliferation (b) by sorafenib in HepG2, Hep3b, Huh7, and human primary hepatocytes. Caspase-3 activity was measured by commercial chemiluminescence-based assay as described in Material and Methods. Cell proliferation was determined by BrdU incorporation as described in Material and Methods. The variables were evaluated 24 hr after sorafenib (0, 10 nM, 10 µM, and 100 µM) administration. Results are expressed as mean ± standard error of the mean of 3-5 independent experiments. *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001 between control and sorafenib-treated cells. The groups with different letters (a, b, or c) were significantly different (p ≤ 0.05) through PERK and IRE1 pathways that are related to increased apoptosis and autophagy markers respectively in HepG2 and PLC/PRF/5. In agreement with these studies, our data showed that sorafenib (≥10 µM) not only increased the ratio of Ser51 P-eIF2α/eIF2α protein expression (Figure 3a ) and the protein expression of the C/EBP homologous protein (GADD153 or CHOP; Figure 3b ) at 6 hr, but also that of IRE1α (Figure 3c) , and the mRNA expression of XBP1s/XBP1 ratio (Supporting Information Figure S2 ) at 12 hr.
Interestingly, we have observed that sorafenib reduced ATF6 protein expression (Figure 3d ) at the same range of concentration and time period as increased PERK and IRE1 pathways (Figure 3a and 3c, respectively). inhibits mTOR and triggers autophagy in breast, ovarian, and cervical cancer cell lines (Brüning, Rahmeh, & Friese, 2013) . Sorafenib promoted an early perturbation of the mitochondrial function, ATP depletion and AMPK-dependent inhibition of the mTORC1 pathway in breast cancer cells (Fumarola et al., 2013) . In addition, the sustained activation of phosphatidylinositol 3-Kinase (PI3K)/AKt upregulating mTOR has also been related to sorafenib resistance in HCC cells (Chen et al., 2011 ). In the current study, we observed that sorafenib (10 µM) caused an early and progressive reduction (3-24 hr) of Ser2481 P-mTOR phosphorylation in HepG2 (Figure 4a ), as well as in Hep3B and Huh7 cells (Supporting Information Figure S3 ). Sorafenib (10 µM) induced an early upregulation of Thr308 P-AKt phosphorylation (6-12 hr) followed by downregulation of Thr308 P-Akt and Ser473 P-Akt phosphorylation (24-48 hr; Figure 4b ).
| Sorafenib decreased
Sorafenib also induced a rapid and transient increase of The inhibition of mTOR by sorafenib has a great impact on protein translation. The polysome profiles in control cells were obtained by observing free 40S and 60S ribosomal subunits, 80S
ribosomes, and actively translating polysomes. However, sorafenib (10 µM) resulted in abnormal polysome profiles, with a dramatic increase of the 80S peak and a reduction of polysomes (Figure 4d ).
Salt treatment dissociated most of the 80S peak into free 40S and 60S ribosomal subunits, indicating that the large 80S ribosome population was mostly nontranslating vacant ribosomes rather than monosomes engaged with mRNA (Supporting Information Figure S4 ).
The nutrient deprivation, growth factor withdrawal or hypoxia are related to autophagy induction (He & Klionsky, 2009) showed that autophagy induced by sorafenib (10 µM) was only transiently active (6-12 hr).
| The inhibition of the ER stress and AMPK downregulated autophagy and increased apoptosis in sorafenib-treated HepG2 cells
We have evaluated the specific role of ER stress arms and AMPK on autophagy and apoptosis using si-RNA technology and dorsomorphin, respectively. Data showed that IRE1α and PERK were deeply involved in sorafenib-induced autophagy, whereas a minor effect of ATF6 was also observed (6 hr; Figure 6a ). Thus, the reduction of autophagy by si-IRE1α and si-PERK increased sorafenib Figure 7a and Supporting Information S6a and S6b. The line chart in Figure 7b shows the profile throughout time in the expression of mentioned proteins. Our data suggest that sorafenib (10 µM) induced a rapid drop of Mcl-1 protein expression, as well as transient and moderate increase of tBid, Bim EL Bcl-2 and Bcl-xL (3-6 hr) overlapping with the increase of Beclin-1 (3-12 hr). The expression of tBid drastically dropped below the control value at 6 hr, and Bcl-2, Bcl-xL and Beclin-1 expressions were reduced at 12 hr after sorafenib treatment (Figure 7b ). Among the proapoptotic members, only Bim EL showed a sustained increase throughout the kinetic study, reaching the highest value at 24 hr ( Figure 7) . Bak also showed a moderate rise throughout the study, while Bax expression increased transiently (3-6 hr) returning expression to the control level ( Figure 7 ).
The activation of JNK has been related either to ER-related autophagy (Ogata et al., 2006) or apoptosis (Dhanasekaran & Reddy, 2008) (Antar, Kharfan-Dabaja, Mahfouz, & Bazarbachi, 2015; Chi et al., 2008; Escudier et al., 2007; Luo et al., 2014) . Although sorafenib has been effective in extending the overall F I G U R E 5 Evaluation of autophagic flux (a), presence of autophagolysosomes by electronic transmission microscopy (b) and expression of autophagy markers p62, Beclin-1, and LC3II/I (c) in HepG2 cells treated with sorafenib (10 nM and 10 µM). The autophagic flux was assessed in HepG2 transfected with double-tagged pDest-LC3-GFP-mCherry plasmid, which is a pH-sensitive sensor to monitor autophagy in live cells (6 hr). The GFP tag is acid-sensitive while the mCherry tag is acid-insensitive. Yellow merge punctate structures indicate autophagosomes which neutral pH allows both tags emit fluorescent light resulting in a yellow staining. Subsequent fusion of autophagosomes with lysosomes results in red-positive acidic vacuoles where the green fluorescence from GFP is lost. Arrows indicate a typical example of colocalized particles of GFP and mCherry signal, while the arrowhead indicates a typical example of a particle with mCherry signal but without GFP signal due to its degradation. Sorafenib was used at a concentration of 10 µM, while EBSS was used as positive control treatment and chloroquine (50 µM) was used to inhibit autophagic flux. The presence of autophagolysosomes in HepG2 cells treated with sorafenib (10 µM) was also detected by transmission electronic microscopy (12 hr) following the procedure described in Material and Methods. The protein expression of autophagy markers (p62, Beclin-1, and LC3 II/I) was assessed at 6, 12 and 24 hr in sorafenib (10 nM and 10 µM)-treated HepG2 cells by western-blot procedure as described in Material and Methods. Results are expressed as mean ± standard error of the mean, and with the blots and images are representative of four independent experiments. *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001 between control and sorafenib-treated cells. The groups with different letters (a, b, c, or d) were significantly different (p ≤ 0.05) [Color figure can be viewed at wileyonlinelibrary.com] F I G U R E 6 Effect of knock-down of ER stress branches, and inhibition of AMPK and autophagy in sorafenib-induced autophagy and apoptosis in HepG2. HepG2 cells were first transfected with IRE1α, PERK, and ATF6 si-RNA duplexes for 48 hr to assess their role in autophagy (a) and apoptosis (b,c). The expression of IRE1α, Ser51 P-eIF2α/eIF2α and ATF6 was determined to validate si-IRE1α, si-PERK, and si-ATF6 treatments (a). Afterwards, cells were treated for 6 hr with sorafenib (10 nM and 10 µM) and harvested for analysis. The inhibition of AMPK was carried out by dorsomorphin (5 µM) with or without coadministration with sorafenib (10 µM) being measured FOXO3a/FOXO3a, and Beclin-1 (d) as well as caspase-3 activity (e) and cleaved PARP (f) at 12 and 24 hr. The inhibition of autophagy by 3-methyl adenine (3MA; 5 µM) or chloroquine (50 µM) administered 2 hr before sorafenib (10 µM) induced caspase-3 activity (g) and cleaved PARP protein expression (h) at 24 hr. Autophagy was biochemically followed by the measurement of p62, Beclin-1 and LC3II/I protein expression by western-blot analysis as described in Material and Methods. Apoptosis was analyzed by caspase-3 activity and cleaved PARP protein expression as described in Material and Methods. Results are expressed as mean ± standard error of the mean, and with the blots are representative of four independent experiments. *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 between Control and sorafenib-treated cells. The groups with different letters (a, b, c, d , e, or f) were significantly different (p ≤ 0.05). AMPK, 5′AMP-activated protein kinase; ER, endoplasmic reticulum; PERK, pancreatic ER kinase (PKR)-like ER kinase survival of patients, only a minor percentage of patients (2%) displayed partial response to therapy based on response evaluation criteria in solid tumors (RECIST) criteria (Llovet et al., 2008) , the low response rate being mainly attributed to intrinsic resistance of HCC cells to sorafenib (Villanueva & Llovet, 2012) . Several studies have provided mutational profile and identified an average of 30-40 mutations per tumor; among which 5-8 might be driver mutations, as well as high-level amplifications of oncogenes in specific chromosome RODRÍGUEZ-HERNÁNDEZ ET AL.
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F I G U R E 7 Kinetic study of the expression of Bcl-2 family members and Beclin-1 (a,b), JNK phosphorylation (c), and its inhibition on JNK phosphorylation (d), cell proliferation (e) and caspase-3 (f), as well as Foxo3a phosphorylation (g) in sorafenib-treated HepG2 cells. The effect of sorafenib (10 nM and 10 µM) on the expression of Bcl-2 family members and Beclin-1 were followed at 3, 6, 12, and 24 hr by western-blot analysis. The effect of sorafenib (10 nM and 10 µM) on the Thr183,Tyr185 P-JNK1/2/JNK1/2 and Thr32 P-Foxo3a/Foxo3a protein expression ratio was determined at different time points according to the experiment (3-48 hr). The inhibition of JNK was assessed by the administration of SP600125 (20 µM) added to cell culture 12 hr before sorafenib (10 µM) treatment. Cell proliferation was determined by BrdU incorporation as described in Material and Methods. Caspase-3 activity was measured by commercial chemiluminescence-based assay as described in Material and Methods. Results are expressed as mean ± standard error of the mean, and with the blots are representative of four independent experiments. *p ≤ 0.05 and **p ≤ 0.01 between control and sorafenib-treated cells. The groups with different letters (a, b, c, d , e, or f) were significantly different (p ≤ 0.05). JNK, c-Jun-N-terminal kinase regions. All influence high resistance and reduced extended survival rate during sorafenib treatment in HCC (Llovet, Villanueva, Lachenmayer, & Finn, 2015) .
Sorafenib triggers antiproliferative and antiangiogenic effects through inhibition of the activity of several tyrosine kinase receptors including VEGFR-2/3, PDGFR-β, Flt3, and c-Kit, nonreceptor tyrosine kinase receptors such as Flt3, as well as Raf serine/threonine kinase (Cervello et al., 2012; Wilhelm et al., 2004) . Antiproliferative and antiangiogenic effects induced by sorafenib, both in vitro and in vivo conditions, are driven through different mechanisms and promote apoptosis via both the extrinsic and the intrinsic pathway in HCC cells (Fernando et al., 2012) Figure S1 ). Sorafenib also increased Beclin-1 and LC3II/LC3I, but did not reduce the p62 expression in tissue homogenate, which may reflect high autophagic turnover in coexistence with apoptotic processes (Figure 1d ). The effectiveness of sorafenib is probably a result of a balance between targeting cancer cells and the microenvironment (Llovet et al., 2015) . In this sense, it is interesting to notice that the administration of sorafenib reduced fibrogenesis (α-SMA), angiogenesis (CD31), and the presence of hematopoietic stem cells (CD34) in tumors (Supporting Information Figure S1 ).
These results, as well as those related to the antiproliferative 704 | RODRÍGUEZ-HERNÁNDEZ ET AL.
F I G U R E 8 Effect of knock-down of Bim, Bak, and Bax on caspase-3 activity (a) and autophagic markers (p62, Beclin-1, and LC3II/I) (b), as well as the binding capacity of Beclin-1 to Bim, Bak, and Bax (c) in sorafenib-treated HepG2 cells. The expression of Bim, Bak, and Bax was determined to validate si-Bim, si-Bak, and si-Bax treatments (a). The variables were determined at 24 hr after sorafenib (10 µM) administration. Caspase-3 activity was measured by commercial chemiluminescence-based assay as described in Material and Methods. The protein expression of autophagy markers and proapoptotic Bcl-2 family members was assessed by western-blot analysis. The immunoprecipitation procedure of Beclin-1 is described in Material and Methods. The immunoprecipitation using unspecific mouse IgG and anti-Beclin-1 antibodies were run in parallel. The expression of Bim, Bak, and Bax has also been measured in the cell lysate. Results are expressed as mean ± standard error of the mean, and with the blots are representative of eight independent experiments. *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001 between control and sorafenib-treated cells. The groups with different letters (a, b, c, and d) were significantly different (p ≤ 0.05) properties of the drug, are mostly dependent on the inhibition of tyrosine kinase receptors and the Raf/MEK/ERK.
The mechanism by which sorafenib induces apoptosis is not fully elucidated, and the effectiveness and adverse events are related to the dose used. The mean trough sorafenib concentration is 4.3 ± 2.5 mg/L in cancer patients under sorafenib monotherapy with the recommended dose (400 mg, 12 hr), which are increased up to 7.7 ± 3.6 mg/L in patients who experienced grade 3 drug-related adverse events (Blanchet et al., 2009) . The corresponding therapeutic concentration of sorafenib used in the study is 10 µM. It has been associated with the inhibition of phosphorylation of the initiation factor eIF4E and loss of the antiapoptotic Bcl-2 family members
Mcl-1 which appear to occur through a MEK/ERK independent mechanism in different cancer cell lines treated with sorafenib (Rahmani, Davis, Bauer, Dent, & Grant, 2005; Yu et al., 2005) . Mcl-1, an antiapoptotic member of the Bcl-2 family, has been shown to be an important factor for apoptosis resistance in HCC (Fleischer et al., 2006) . Sorafenib (10 µM) reduced the level of P-eIF4E and Mcl-1 at 2 and 16 hr after treatment in HepG2 and PLC/PRF/5 cells (Liu et al., 2006) . However, we found that there is no temporal relationship One well-characterized function of mTORC1 is to maintain protein synthesis through phosphorylation of at least two direct targets, eukaryotic initiation factor (eIF) 4E-binding proteins (4E-BPs) and ribosomal protein S6 kinases (S6Ks) (Hay & Sonenberg, 2004) . mTOR is regulated by different cell signaling involving ER stress, AKt, and AMPK (Rashid, Yadav, Kim, & Chae, 2015) . The induction of PERK signaling by antitumoral drugs inhibits mTOR and triggers autophagy in different cancer cell lines (Bruning et al., 2013) . Sorafenib (10 µM) significantly increased PERK-and IRE1α-related signaling at 6 hr in HepG2 cells (Figure 3) . The significant reduction of ATF6 (Figure 3d) may be related to the alteration of trafficking between the ER and the Golgi apparatus, as well as the overall secretory pathway induced by sorafenib (Yi et al., 2012) . The activation of PERK and IRE1α signaling was associated with alteration of (Figure 4a ). In addition, the early downregulation of mTOR activation appeared not to be related to reduced AKt phosphorylation.
In fact, Thr308 P-AKt increased 6-12 hr after sorafenib administration in HepG2 (Figure 4b ). The activation of survival pathways on mTOR inhibition has been associated with upregulation of IGF-I receptor in breast (O'Reilly et al., 2006) and rhabdomyosarcoma (Wan, Harkavy, Shen, Grohar, & Helman, 2007) The most important pathways involved in autophagy modulation are mTORC1 and AMPK (Prieto-Dominguez et al., 2016) . The inhibition of mTOR by sorafenib appeared to be stronger in HepG2 (Figure 4a ) than in Hep3B and Huh7 (Supporting Information Figure S3) . However, the activation of autophagic process using the tandem pDest-LC3-GFPmCherry plasmid transfected to sorafenib-treated cells (Figure 5a Urano et al. (2000) reported that ER stress and, in particular the IRE1 kinase activity, increases JNK activity. The autophagic process, as apoptosis, appeared to be tightly regulated by anti-and proapoptotic members of the Bcl-2 family. The activation of the autophagic process (6-12 hr) by sorafenib was associated with a drastic increase of Beclin-1 expression, which it was preceded by rapid downregulation of Mcl-1 and upregulation of tBid and Bim EL , while Bcl-2 and Bcl-xL remained at moderate levels during this period after drug administration (Figure 7a and 7b, and Supporting Information Figure S6 ). Interestingly, tBid and Bim EL have been shown to promote autophagy by displacing Beclin-1 from its interaction with Bcl-2 (Erlich et al., 2007; Marquez & Xu, 2012) .
In fact, Beclin-1 has been identified as a BH3-only protein (Maiuri et al., 2007) that allows its interaction with Bcl2 and its homologue Bcl-xL (Oberstein, Jeffrey, & Shi, 2007) . The expression of Beclin-1 (Park et al., 2009 ) and Bcl-2 phosphorylation that disrupts Beclin-1-Bcl-2 complex-1 (Wei, Pattingre, Sinha, Bassik, & Levine, 2008) have been related to the activation of JNK1. It was interesting to observe that Thr183, Tyr185 P-JNK1/ 2/JNK1/2 was induced by sorafenib (10 µM) during the period in which autophagy was activated (3-12 hr; Figure 7c ). The inhibition of The activation of apoptosis by sorafenib was coincident with a sustained increase in Bim EL expression, remaining Bak and Bax at a moderate expression level (Figure 7a and 7b, and Supporting Information Figure S6 ). JNK has also been observed to induce phosphorylation of Bim, promoting its release from its binding to dynein and myosin V motor complexes (Lei & Davis, 2003) . Sorafenib (10 µM) induced a sustained and progressive increase of CHOP expression (6-24 hr; Figure 3b ). The main effector of PERK-mediated apoptosis is the proapoptotic transcription factor CHOP which can be induced by ATF4, ATF6, as well as XBP1s (Verfaillie, Salazar, Velasco, & Agostinis, 2010) . Interestingly, CHOP suppresses the expression of the antiapoptotic Bcl-2 (McCullough, Martindale, Klotz, Aw, & Holbrook, 2001 ) and promotes the transcription of the proapoptotic BH3-only protein Bim (Puthalakath et al., 2007) . The induction of thapsigargin-induced ER has also been related to a stabilization of Bim by PP2A-related dephosphorylation that prevents its ubiquitination and degradation, as well as by transcriptional regulation though CHOP-ATF4 in breast cancer cells (Puthalakath et al., 2007) . The expression of Bim is also under positive transcriptional regulation of Foxo3a (Nakamura & Sakamoto, 2008) whose activity is regulated by a plethora of kinases such as GSK3β, MST1, JNK, CS1, AMPK, and AKt (Farhan et al., 2017) . As described above, a positive correlation appeared between Thr172 P-AMPK/AMPK ratio and related activation phosphorylation of Ser413 P-Foxo3a/Foxo3a ratio (Figure 6d ). In addition, PI3K/AKt survival signaling increases the inhibitory phosphorylation Thr32 P-Foxo3a, preventing its nuclear translocation and transcriptional activity (Brunet et al., 1999) . Our study also showed that the expression of Bim EL raised shortly after sorafenib administration which was maintained at moderate expression levels during autophagic-related phase (6-12 hr). This expression level might be the result of the interaction between the upregulation of and Noxa, induce autophagy by disrupting the Beclin-1-Bcl2 complex (Marquez & Xu, 2012) . The immunoprecipitation studies demonstrated the formation of Beclin-1 and Bim complex (Figure 8c ). In this sense, our study may also suggest that the absence of Bim by si-RNA promotes the induction of early autophagic structures by sorafenib (10 µM) independently of Beclin-1 expression which remain at low level at 24 hr (Figure 8b ).
In conclusion, our study showed that the induction of ER stress by sorafenib was the driving mechanism involved in the sequential induction of autophagy and apoptosis in HepG2 cells (Figure 9 ). The early sorafenib-induced ER stress and regulation of JNK and AMPKdependent signaling were related to the induction of survival autophagic process (3-12 hr). The sustained treatment with sorafenib induced a progressive increase of ER stress and PERK-CHOPdependent rise of Bim EL , which induced the shift from autophagy to apoptosis (24 hr). However, the kinetic of Bim EL expression profile might also be related to the tight balance between AKt-and AMPKrelated signaling in Foxo3a-dependent Bim EL upregulation.
